IRVINE, Calif., April 25, 2012 /PRNewswire/ -- AtheroNova
Inc. (OTCBB: AHRO), a biotech company focused on the research and
development of compounds to regress atherosclerotic plaque, today
announced that it has signed an agreement with Frontage
Laboratories, Inc. to commence work on the formulation, compounding
and tabletization of the Company's AHRO-001 product in advance of
the upcoming Phase I human clinical studies. Frontage, based in
Exton, Pennsylvania, is one of the
leading pharmaceutical contract research organizations (CROs) in
the United States. They will immediately commence work on the
analysis, formulation and validation of the various processes and
procedures for manufacturing AHRO-001 tablets.
"Frontage has been extremely diligent in dealing with the
technical and physical requirements of our AHRO-001 compound and we
look forward to commencing our project in the coming days," said
AtheroNova CEO Thomas W.
Gardner. "We are very confident that Frontage will
deliver a quality product in a timely manner. We continue to adhere
to our vigorous development path and anticipate additional exciting
development milestones in the coming months."
"We are pleased to be working with the fine people from Frontage
on this project as we continue to engage with quality industry
partners," commented Dr. Balbir
Brar, Senior Vice President of Drug Development. "Our utmost
confidence stems from previous projects I have worked on with
Frontage and have always found their people, facilities and product
quality to be some of the best in the industry."
Frontage CEO, Dr. Song Li, also
commented on the agreement, stating "It is an honor to work with
AtheroNova on this vital clinical trial materials project.
Frontage's 10-year history of delivering pharmaceutical R&D
services in a fast and efficient manner means the millions of
patients suffering from atherosclerosis are that much closer to a
potential cure."
About AHRO-001
AHRO-001 is AtheroNova's first novel application for the
treatment and prevention of atherosclerosis. Atherosclerotic plaque
is the primary, underlying cause of heart disease and stroke in
industrialized countries. AHRO-001 uses certain pharmacological
compounds to regress atherosclerotic plaque deposits through a
process known as delipidization. Delipidization dissolves plaques
in artery walls, which are then removed by natural body processes.
AtheroNova plans to develop multiple applications for its
patents-pending compounds that can be used in pharmaceutical-grade
products for the treatment of atherosclerosis. Atherosclerosis and
related pharmaceutical costs run more than $41 billion annually in the United States alone. Market sectors
potentially served by AHRO-001 include: Cardiovascular Disease,
Stroke, Peripheral Artery Disease, Dementia and Alzheimer's and
Erectile Dysfunction, all of which have been linked to
atherosclerosis.
About AtheroNova
AtheroNova Inc., through its wholly-owned subsidiary, AtheroNova
Operations, Inc., is an early stage biotech company focused on
discovery, research, development and licensing of novel compounds
to reduce or regress atherosclerotic plaque deposits. The Company's
focus on compounds to reduce or regress atherosclerotic plaque
deposits addresses the most lucrative segments of the multi-billion
dollar prescription drug market: cardiovascular disease and stroke
prevention. www.AtheroNova.com.
About Frontage Laboratories, Inc.
Frontage Laboratories, Inc. is a global contract research,
development and manufacturing organization, offering a full range
of pharmaceutical R&D services. Frontage operates in the
US and China, using one seamless GXP platform (GMP/GLP/GCP).
Frontage runs three Phase 1 Clinical units, an 88-bed Phase 1 Unit
in Hackensack, NJ, a 120-bed Phase
1 Unit in Zhengzhou, Henan Province China, and a-80 bed Phase 1 Unit
in Changchun, Jiling Province
China. Frontage has an AALAC certified preclinical animal
facility in Pennsylvania, where it
also maintains bioanalytical and CMC facilities. In Shanghai and Beijing, China, the company also operates
bioanalytical and CMC facilities. The Frontage CMC Division
provide services in the areas of custom API synthesis and GMP
manufacturing, analytical testing, formulation development and
manufacturing of clinical trial materials including Sterile
(Injection and Ophthalmic), Oral Solid (IR and CR), Topical, and
High Potent products. As a rapidly expanding CRO with ten
years of success providing high-quality GXP services, Frontage has
established an international standard in pharmaceutical product
research, development, quality and management systems.
Forward-Looking Statements
Except for historical information contained herein, the
statements in this release are forward-looking and made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are inherently
unreliable and actual results may differ materially. Examples of
forward-looking statements in this news release include statements
regarding the Company's product shipments, suitability of the
compound for its intended use, mechanisms of action, clinical
trials and supply chain as well as the development of applications
for AtheroNova's technology. Factors which could cause actual
results to differ materially from these forward-looking statements
include such factors as significant fluctuations in expenses
associated with clinical trials, failure to secure additional
financing, the inability to complete regulatory filings with the
Food and Drug Administration, the introduction of competing
products, or management's ability to attract and maintain qualified
personnel necessary for the development and commercialization of
its planned products, and other information that may be detailed
from time to time in AtheroNova's filings with the United States
Securities and Exchange Commission. AtheroNova undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
SOURCE AtheroNova Inc.